Navigation Links
US FDA Grants Orphan Drug Status to Immtech's Pafuramidine for Treatment of African Sleeping Sickness
Date:9/19/2007

n the early stage of the disease. Because pafuramidine is more user-friendly than existing therapies, we anticipate that it would be available in community clinics as well as at current African sleeping sickness treatment centers. Patients could be treated close to home, rather than traveling long distances to specialized centers."

Pafuramidine has previously been granted Orphan Drug Designation for treatment of pneumocystis pneumonia (PCP) and malaria. In addition to trials for African sleeping sickness, pafuramidine is currently in Phase III clinical trials for PCP, and in Phase II trials targeting malaria treatment and malaria prophylaxis.

"This is another positive milestone for Immtech as pafuramidine advances towards commercialization," commented Eric L. Sorkin, Immtech's Chairman and Chief Executive Officer. "We will continue to work closely with our consortium of scientists, and global collaborators to develop safer and more effective therapies for this and other global health threats."

About Immtech Pharmaceuticals, Inc.

Immtech Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat infectious diseases, and the Company is expanding its targeted markets by applying its proprietary pharmaceutical platform to treat other disorders. Immtech has advanced clinical programs that include new oral treatments for Pneumocystis pneumonia (PCP), malaria, and trypanosomiasis (HAT or African Sleeping Sickness), and a well defined, expanding library of compounds targeting drug-resistant Gram-positive bacteria, fungal infections, Hepatitis C and other serious diseases. Immtech holds the exclusive worldwide licenses to certain patents, patent applications and technology for products derived from a proprietary pharmaceutical platform. For additional information, please go to http://www.immtechpharma.com

"Safe Harbor" Statement under the Private Securities Reform Ac
'/>"/>

SOURCE Immtech Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Allos Therapeutics PDX Granted Orphan Medicinal Product Designation by the European Commission
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
5. Point of Care Strep Tests Speed Treatment, Lower Costs
6. Rapid HIV Testing Increases Possibility of Treatment
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Ill. , July 22, 2014  UL ... announced that the U.S. Food and Drug Administration ... as consensus standards for medical devices incorporating lithium ... 2054 - Standard for Household and Commercial Batteries, ... (Cells). Consensus standards are standards ...
(Date:7/22/2014)... N.J. , July 22, 2014  Vernalis plc ... achievement of proof-of-concept (POC) for CCP-08, the third ... prescription cough cold collaboration. Under this collaboration, POC ... a successful human pilot comparative study against an ... achieving POC, Vernalis will make a milestone payment ...
(Date:7/22/2014)... SAN MARCOS, Texas , July 22, 2014 Quantum ... Martin and Mr. John Heaton to the Board ... chaired by Dr. Ghassan Jabbour , QMC Chief Science Officer ... Dr. Michael Wong of Rice University and Mr. ... Japan . " Quantum Materials ...
Breaking Medicine Technology:Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4
... Bowl champion coach, Fox NFL Sunday host and ... ExtenZe, the male enhancement brand, he has good-naturedly taken a ... national television. Now, in this next flight of ... fun, laughing about being put on the spot and made ...
... AMGN ) today announced that results from ... be presented at the 35th European Society for Medical ... "Cancer is a complex disease which ... pathways to develop novel therapies to treat cancer and ...
Cached Medicine Technology:Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His 'Notoriety' in New ExtenZe Spots from Inter/Media Advertising 2Two-Time Super Bowl Champion Coach & Sports Broadcaster Jimmy Johnson Laughs About His 'Notoriety' in New ExtenZe Spots from Inter/Media Advertising 3Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 2Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 3Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 4Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 5Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 6Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 7Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 8Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 9Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 10Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 11Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 12Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 13Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 14Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 15Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress 16
(Date:7/22/2014)... SIMpalm, a leading Mobile App Development ... Payment System. Forte Mobile Payment app allows merchants to ... and iPad. The app was originally launched in ... This update was for iOS 7.0 compatibility and iPhone ... and is available to download on the iPhone app ...
(Date:7/22/2014)... cholesterol treatment and cardiovascular risk assessment state that men ... atherosclerotic cardiovascular disease or of having a heart attack ... profile (based on age, smoking history, and cholesterol and ... when and how aggressively to treat high cholesterol are ... Health , a peer-reviewed publication from Mary Ann Liebert, ...
(Date:7/22/2014)... TX (PRWEB) July 22, 2014 The ... Program and third annual Institute Scholar Program. These offerings ... of the patient experience in healthcare and the need ... , The grant and scholar programs are ... , Value of focusing on the patient ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... Risperdal lawsuits ( http://www.risperdallawsuitcenter.com/ ) in ... his decision to deny punitive damages in cases ... (male breast growth), Bernstein Liebhard LLP reports. In ... New also denied a plaintiffs’ request to certify ...
(Date:7/22/2014)... park is the heart of a community. That’s ... made a recent investment in outdoor recreation and fun ... equipment from American Parks Company™. , The community of ... a 475-unit community that was established in the 1970s. ... tropical paradise with lush shade trees, green-edged walking and ...
Breaking Medicine News(10 mins):Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 2Health News:SIMpalm Launched Updated Forte Mobile Payment App on iPhone and iPad for Its Client 3Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 2Health News:The Beryl Institute Opens Applications for 2014 Patient Experience Grant and Scholar Programs 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuit News: Pennsylvania Judge Won’t Reconsider Denial of Punitive Damages for Risperdal Gynecomastia Plaintiffs, Bernstein Liebhard LLP Reports 4Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 2Health News:Fun in the Florida Sun: Kendalltown Homeowners Association Inc. Expands Outdoor Recreation with American Parks Company™ 3
... with The Bakersfield based Comprehensive Blood and Cancer center (CBCC), ... an other six months the CBCC of US is to ... Kuruvilla the CEO of Apollo Hospital said that, "It will ... have within the hospital premises a separate unit that will ...
... A new ultra light hand, called the 'Southampton Remedi-Hand' has been ... hand better than any currently available. // ,The human hand ... movements and actions. The artificially developed hand is dependent on 6 ... way so as to enable independent movement of all the five ...
... that their neighborhoods are safe then their preschool children ... points out that this does not mean that these ... comparison with their counterparts in unsafe neighborhoods. ,Drawing ... researchers reported these findings in the September issue of ...
... acid as found to reduce the rate of birth defects. ... found that more than one third of birth defects are ... Spina bifida and anencephaly, known as neural-tube defects, arise when ... close during the first weeks of pregnancy. The defect causes ...
... emergency room with cervical spinal injury may have more damage ... published in the Annals of Emergency Medicine, say that CT ... over and above the normal X-rays.// ,The study indicates ... additional spinal damage not visible on regular x-rays. In fact, ...
... announcement the Health Minister of West Bengal Mr.Surya Kanta Mishra ... and the numbers of cases detected were increasing in ... other than dengue, malaria, typhoid, viral fever and encephalitis were ... was also reported in N.Delhi last week in India. Dengue ...
Cached Medicine News:Health News:New ultralight hand with better functionality and flexibility developed 2Health News:Safe Neighborhood Means Less TV For Preschool Children 2Health News:Folic acid enriched grain reduces birth defects 2
BD Vacutainer® Fluoride Tubes - Glass...
BD Vacutainer® Specialty Tubes - Trace Element - Glass...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Plus Plastic Serum Tubes have spray-coated silica and are used for serum determinations in chemistry, serology, and immunohematology....
Medicine Products: